RIVM researchers win best paper award of the journal Risk Analysis RIVM researchers Arie Havelaar and Arno Swart received the prestigious Best Paper Award 2014 of the Society for Risk Analysis.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.
Biobased alternatives to hormone disrupting substance in cash register receipts Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.
European Antibiotic Awareness Day 2014 Tuesday 18 November is European Antibiotic Awareness Day. On this day, throughout Europe, attention is focused on the responsible use of antibiotics for people and animals.
RIVM provides overview of the possible risks of bisphenol A RIVM has created an overview of the possible risks of Bisphenol A (BPA) for humans and the environment. BPA is a component of many different products and affects the endocrine system.
Possibly more cases of gastroenteritis caused by antacids In recent years the Netherlands has witnessed an increase in the number of cases of gastroenteritis caused by the Campylobacter bacterium.
Antibiotic resistance no longer increasing but vigilance remains necessary After continuing to rise for many years, in 2013 the prevalence of resistance to antibiotics levelled out somewhat in both hospitals and primary care.
International top conference about antibiotic resistance On 25 and 26 June, an international conference about resistance to antibiotics - an increasing worldwide problem - will take place in The Hague.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.